Preliminary profile of the antiviral activity, metabolic effects and safety of DMP-450, a novel cyclic urea protease inhibitor.

被引：0
|
作者：
Sierra, J
Nino, S
Volkow, P
Sereni, D
Yeni, P
Staszewski, S
Gatell, J
Wang, L
McMillan, N
Rousseau, F
Miralles, GD
机构：
[1] Clin Barcelona, Barcelona, Spain
[2] Univ Frankfurt, D-6000 Frankfurt, Germany
[3] Hosp Bichat Claude Bernard, Paris, France
[4] Hosp St Louis, Paris, France
[5] Inst Natl Cancerol, Mexico City, DF, Mexico
[6] Inst Natl Nutr, Mexico City, DF, Mexico
[7] Triangle Pharmaceut Inc, Durham, NC USA
来源：
CLINICAL INFECTIOUS DISEASES | 2000年 / 31卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
340
引用
收藏
页码：271 / 271
页数：1
相关论文
共 14 条
  • [1] P-glycoprotein effects of cyclic urea HIV protease inhibitor DMP 323 in competitional absorption studies
    Richter, Martin
    Gyemant, Nora
    Molnar, Josef
    Hilgeroth, Andreas
    ARCHIV DER PHARMAZIE, 2006, 339 (11) : 625 - 628
  • [2] The Antiviral Profile of TG-2349, a novel HCV Protease Inhibitor with Pan-Genotypic Activity
    Chen, Chih-Ming
    Chen, Yi-Fen
    Lin, Chu-Chung
    King, Chi-Hsin R.
    Hsu, Ming-Chu
    HEPATOLOGY, 2014, 60 : 1172A - 1172A
  • [3] Improved cyclic urea inhibitors of the HIV-I protease: Synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450
    Hodge, CN
    Aldrich, PE
    Bacheler, LT
    Chang, CH
    Eyermann, CJ
    Garber, S
    Grubb, M
    Jackson, DA
    Jadhav, PK
    Korant, B
    Lam, PYS
    Maurin, MB
    Meek, JL
    Otto, MJ
    Rayner, MM
    Reid, C
    Sharpe, TR
    Shum, L
    Winslow, DL
    EricksonViitanen, S
    CHEMISTRY & BIOLOGY, 1996, 3 (04): : 301 - 314
  • [4] Antiviral activity and resistance profile of AG-001859, a novel HIV-1 protease inhibitor with potent activity against protease inhibitor-resistant strains of HIV
    Hammond, J
    Jackson, L
    Graham, J
    Knowles, S
    Digits, J
    Tatlock, J
    Jewell, T
    Canan-Koch, S
    Patick, AK
    ANTIVIRAL THERAPY, 2004, 9 (04) : U29 - U29
  • [5] In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450
    Pilot-Matias, Tami
    Tripathi, Rakesh
    Cohen, Daniel
    Gaultier, Isabelle
    Dekhtyar, Tatyana
    Lu, Liangjun
    Reisch, Thomas
    Irvin, Michelle
    Hopkins, Todd
    Pithawalla, Ron
    Middleton, Timothy
    Ng, Teresa
    McDaniel, Keith
    Or, Yat Sun
    Menon, Rajeev
    Kempf, Dale
    Molla, Akhteruzzaman
    Collins, Christine
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (02) : 988 - 997
  • [6] Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor
    Sevigny, G.
    Stranix, B.
    Tian, B.
    Dubois, A.
    Sauve, G.
    Petropoulos, C.
    Lie, Y.
    Hellmann, N.
    Conway, B.
    Yelle, J.
    ANTIVIRAL RESEARCH, 2006, 70 (02) : 17 - 20
  • [7] In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1
    Dandache, Serge
    Sevigny, Guy
    Yelle, Jocelyn
    Stranix, Brent R.
    Parkin, Neil
    Schapiro, Jonathan M.
    Wainberg, Mark A.
    Wu, Jinzi J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (11) : 4036 - 4043
  • [8] Three-dimensional solution structure of the HIV-1 protease complexed with DMP323, a novel cyclic urea-type inhibitor, determined by nuclear magnetic resonance spectroscopy
    Yamazaki, T
    Hinck, AP
    Wang, YX
    Nicholson, LK
    Torchia, DA
    Wingfield, P
    Stahl, SJ
    Kaufman, JD
    Chang, CH
    Domaille, PJ
    Lam, PYS
    PROTEIN SCIENCE, 1996, 5 (03) : 495 - 506
  • [9] GS-8374, a novel phosphonate HIV protease inhibitor with potent in vitro antiretroviral activity, low metabolic toxicity, and favorable resistance profile
    Callebaut, Christian
    Stray, Kirsten
    Tsai, Luong
    Xu, Lianhong
    He, Gong-Xin
    Mulato, Andrew
    Priskich, Tina
    Parkin, Neil
    Lee, William
    Cihlar, Tomas
    ANTIVIRAL RESEARCH, 2007, 74 (03) : A27 - A27
  • [10] ANTIVIRAL ACTIVITY, SAFETY AND PHARMACOKINETICS OF IDX320, A NOVEL MACROCYCLIC HCV PROTEASE INHIBITOR, IN A 3-DAY PROOF-OF-CONCEPT STUDY IN PATIENTS WITH CHRONIC HEPATITIS C
    Reesink, Hendrik W.
    van Vliet, Andre A.
    Muehr, F.
    Weegink, Christine J.
    Mazur, Wlodzimierz W.
    Wiercinska-Drapalo, Alicja
    Simon, K.
    Cholewinska-Szymanska, G.
    Kapocsi, J.
    Varkonyi, I.
    Zhou, Xiao-Jian
    Temam, Marie-Francoise
    Molles, Jeffrey
    Chen, Jie
    Pietropaolo, Keith
    Sullivan-Bolyai, John
    Mayers, Douglas L.
    HEPATOLOGY, 2010, 52 (04) : 882A - 883A
12